Targeted therapy of EGFR mutated lung adenocarcinoma as neoadjuvant treatment followed lung resection ? case report.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F12%3A%230000138" target="_blank" >RIV/26475821:_____/12:#0000138 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Targeted therapy of EGFR mutated lung adenocarcinoma as neoadjuvant treatment followed lung resection ? case report.
Original language description
Molecular targeted therapy with tyrozine kinase inhibitors that block the activation cascade of epidermal growth factor receptor (EGFR-TKI) is indicated on the first line in patients carrying activating mutations of EGFR gene. Patients with adenocarcinoma have increased frequency of activating mutations and therefore have a significantly better profit from this treatment. Genetic testing of EGFR mutations in patients with advanced NSCLC should be now a standard part of diagnostic procedure, however an ongoing search for other potential predictors of biologically targeted therapies is essential.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9718" target="_blank" >NS9718: New possibilities for application of molecular-diagnostic methods for early detection and proper therapy selection of progressing Non-Small Cell Lung Cancer based on detection and monitoring of hypermethylation of specific genes</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů